From barriers to cloud-based regulatory collaboration: An industry perspective on accelerating innovation in...

Pharmaceutical manufacturing is changing rapidly as new therapeutic modalities, advanced manufacturing approaches, modern analytical tools, and novel drug-delivery technologies continue to emerge. While the scientific and technical potential of these innovations is clear, their adoption has often lagged due to regulatory challenges. Differences in regulatory expectations across regions, lengthy review timelines, and limited opportunities for coordinated engagement can slow or discourage the implementation of meaningful chemistry, manufacturing, and controls (CMC) advances. This review considers these barriers from an industry perspective, drawing attention to how cautious regulatory paradigms, fragmented guidance, and market-specific interpretations can reduce the incentive to introduce innovation, even when patient benefit is evident. Recent surveys, regulatory initiatives, and collaborative experiences suggest that progress is being made, particularly through innovation programs and reliance-based mechanisms; however, gaps remain in achieving consistent alignment and efficient lifecycle management. Looking ahead, greater use of cloud-based platforms to support real-time information sharing and collaborative regulatory review offers a practical path forward. Such approaches can improve transparency, reduce duplicate interactions, and encourage convergence without compromising regulatory rigor. By aligning regulatory practices more closely with scientific progress and the demands of today's advanced manufacturing, digital, and other 21st-century technologies, these collaborative models have the potential to accelerate innovation, support continuous improvement, and enable more timely global access to medicines.